Lígia Campos
About Lígia Campos
Current Title at BeiGene
Lígia Campos currently holds the position of Director, Clinical Operations Head Brazil at BeiGene. In this role, she oversees the clinical operations for the Brazilian division of the company, leveraging her extensive experience in the field of oncology clinical research.
Previous Roles at Novartis
Prior to her current position, Lígia Campos built an impressive career at Novartis, where she held multiple roles over a span of eight years. She served as Clinical Operations Head (RWE) - Oncology Medical Affairs from 2019 to 2022, focusing on real-world evidence generation for oncology products. Before that, she was a Medical Science Liaison - Oncology from 2018 to 2019, and a Clinical Study Manager - Oncology from 2016 to 2018. Campos initially joined Novartis as a Clinical Research Project Coordinator - Oncology in 2014 and as a Clinical Research Associate - Oncology from 2008 to 2014 in São Paulo, Brazil.
Early Career in Clinical Research
Lígia Campos began her career at Aché Laboratórios Farmacêuticos as a Clinical Research Associate, working from 2007 to 2008 in São Paulo, Brazil. She then moved to a specialized ambulatory for HIV/AIDS as a Pharmacist for a brief period in 2007 before joining Novartis. These early roles provided her with foundational experience in clinical research and operations.
Educational Background
Lígia Campos completed her Bachelor of Pharmacy (B.Pharm.) in Pharmaceutical Sciences from the Pontifícia Universidade Católica de Campinas (PUCCAMP). Her education provided a strong scientific foundation, enabling her to excel in various roles within the pharmaceutical industry.
Experience in Oncology Clinical Research
With over 15 years of experience in oncology clinical research, Lígia Campos has developed expertise in managing clinical trial operations, particularly focusing on solid tumors such as breast, lung, and melanoma, as well as hematologic malignancies. Her experience spans leading clinical operations and generating high-quality evidence to support product decisions and market access strategies.